Hanspeter Gubler
Overview
Explore the profile of Hanspeter Gubler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
102
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mesrouze Y, Gubler H, Villard F, Boesch R, Ottl J, Kallen J, et al.
ACS Chem Biol
. 2023 Feb;
18(3):643-651.
PMID: 36825662
The TEAD transcription factors are the most distal elements of the Hippo pathway, and their transcriptional activity is regulated by several proteins, including YAP. In some cancers, the Hippo pathway...
2.
Renner S, Bergsdorf C, Bouhelal R, Koziczak-Holbro M, Amati A, Techer-Etienne V, et al.
Sci Rep
. 2020 Jun;
10(1):9670.
PMID: 32541899
Multiplexed gene-signature-based phenotypic assays are increasingly used for the identification and profiling of small molecule-tool compounds and drugs. Here we introduce a method (provided as R-package) for the quantification of...
3.
Gubler H, Clare N, Galafassi L, Geissler U, Girod M, Herr G
SLAS Discov
. 2018 Jan;
23(5):474-488.
PMID: 29370716
We describe the main characteristics of the Novartis Helios data analysis software system (Novartis, Basel, Switzerland) for plate-based screening and profiling assays, which was designed and built about 11 years...
4.
Gubler H, Schopfer U, Jacoby E
J Biomol Screen
. 2012 Aug;
18(1):1-13.
PMID: 22853931
The four-parameter logistic Hill equation models the theoretical relationship between inhibitor concentration and response and is used to derive IC(50) values as a measure of compound potency. This relationship is...
5.
Kummel A, Selzer P, Beibel M, Gubler H, Parker C, Gabriel D
J Biomol Screen
. 2011 Feb;
16(3):338-47.
PMID: 21335595
High-content screening (HCS) is increasingly used in biomedical research generating multivariate, single-cell data sets. Before scoring a treatment, the complex data sets are processed (e.g., normalized, reduced to a lower...
6.
Varin T, Gubler H, Parker C, Zhang J, Raman P, Ertl P, et al.
J Chem Inf Model
. 2010 Nov;
50(12):2067-78.
PMID: 21073183
The main goal of high-throughput screening (HTS) is to identify active chemical series rather than just individual active compounds. In light of this goal, a new method (called compound set...
7.
Kummel A, Gubler H, Gehin P, Beibel M, Gabriel D, Parker C
J Biomol Screen
. 2009 Nov;
15(1):95-101.
PMID: 19940084
Methods that monitor the quality of a biological assay (i.e., its ability to discriminate between positive and negative controls) are essential for the development of robust assays. In screening, the...
8.
Gubler H
Methods Mol Biol
. 2009 Jun;
552:79-95.
PMID: 19513643
An overview of the characteristics of classical and outlier-resistant data summaries is provided. The latter are important because outlier data can skew results and decisions based on them. The simple...
9.
Unterreiner V, Ibig-Rehm Y, Simonen M, Gubler H, Gabriel D
J Biomol Screen
. 2009 Jan;
14(1):59-65.
PMID: 19171921
High-content screening (HCS), a technology based on subcellular imaging by automated microscopy and sophisticated image analysis, has emerged as an important platform in small-molecule screening for early drug discovery. To...
10.
Imbert P, Unterreiner V, Siebert D, Gubler H, Parker C, Gabriel D
Assay Drug Dev Technol
. 2007 Jul;
5(3):363-72.
PMID: 17638536
Time-resolved (TR) fluorescence resonance energy transfer (FRET) is a widely accepted technology for high throughput screening (HTS), being able to detect and quantify the interactions of specific biomolecules in a...